| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Jun 8, 2011 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 2010-05-13 (see label) | approved | May 13, 2010 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 2007-09-28 (see label) | approved | Sep 28, 2007 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 2006-10-17 (see label) | approved | Oct 17, 2006 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 2006-03-22 (see label) | approved | Mar 22, 2006 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 2004-08-18 (see label) | approved | Aug 18, 2004 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 2004-05-19 (see label) | approved | May 19, 2004 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 2002-11-27 (see label) | approved | Nov 27, 2002 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 1999-12-23 (see label) | approved | Dec 23, 1999 | openfda |
| Docetaxel | US FDA | — | Efficacy supplement 1998-06-22 (see label) | approved | Jun 22, 1998 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | May 14, 1996 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | May 14, 1996 | openfda |
| Ibrutinib | US FDA | — | Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) • . Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion • . Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy | approved | Aug 24, 2022 | openfda |
| Ibrutinib | US FDA | — | Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) • . Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion • . Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy | approved | Feb 16, 2018 | openfda |
| Ibrutinib | US FDA | — | Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) • . Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion • . Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy | approved | Feb 16, 2018 | openfda |
| Ibrutinib | US FDA | — | Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) • . Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion • . Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy | approved | Feb 12, 2014 | openfda |
| Ibrutinib | US FDA | — | Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) • . Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion • . Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy | approved | Nov 13, 2013 | openfda |
| Idelalisib | EU EMA | — | Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment. | approved | Sep 18, 2014 | ema |
| Venetoclax | EU EMA | — | Venclyxto is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL): in combination with acalabrutinib with or without obinutuzumab in combination with obinutuzumab in combination with ibrutinib Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venclyxto monotherapy is indicated for the treatment of CLL: in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor. Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. | approved | Dec 4, 2016 | ema |